Table 1 Baseline characteristics for demographic, clinical and laboratory parameters
Number of patients | 55 |
|---|---|
Sex (women/men) | 37/18 (67/33) |
Age (years) | 62 ± 15 |
BSA (m2) | 1.9 ± 0.2 |
Etiology of pulmonary hypertension | |
Group I (pulmonary arterial hypertension, PAH) | 40 (73) |
Group II (due to left heart disease) | 5 (9) |
Group III (due to lung diseases and/or hypoxia) | 1 (2) |
Group IV (due to chronic thromboembolism) | 9 (16) |
Group V (unclear and/or multifactorial mechanisms) | 0 (0) |
Laboratory parameters | |
NT-proBNP (ng/L) | 979 [329–2286] |
Saturation peripheral (%) | 93 ± 4 |
Comorbidites | |
Diabetes | 14 (26) |
Hypertension | 13 (24) |
Coronary artery disease | 7 (13) |
Chronic obstructive pulmonary diseases | 7 (13) |
Obstructive sleep apnea syndrome | 1 (3) |
6-min walking test (m) | 325 [200–412] |
Functional class, NYHA | |
I | 3 (6) |
II | 29 (53) |
III | 19 (35) |
IV | 4 (7) |
Medication | |
O2 | 14 (26) |
Diuretics | 26 (47) |
Calcium antagonists | 10 (18) |
ACE/ARB blockers | 13 (24) |
Beta blockers | 14 (26) |
Nitrates | 3 (6) |
ERA | 8 (15) |
PDE5I | 8 (15) |
Prostanoids | 1 (2) |
sGCS | 1 (2) |